Vertex Pharmaceuticals Patents – Key Insights and Stats

Vertex Pharmaceuticals has a total of 12016 patents globally, out of which 5124 have been granted. Of these 12016 patents, more than 37% patents are active. United States of America is where Vertex Pharmaceuticals has filed the maximum number of patents, followed by Europe and Japan. Parallelly, USA seems to be the main focused R&D center and also is the origin country of Vertex Pharmaceuticals.

Vertex Pharmaceuticals was founded in 1989 by Joshua Boger. Vertex Pharmaceuticals discovers, develops, and commercializes pharmaceutical products. The Company develops drugs for the treatment of cystic fibrosis, cancer, inflammatory bowel, autoimmune disease, and neurological disorders. Vertex Pharmaceuticals serves healthcare sector worldwide. As of May 2022, Vertex Pharmaceuticals has a market cap of $69.57 Billion.

Read about some of the most popular patents of Vertex Pharmaceuticals which have been covered by us in this article and also you can find Vertex Pharmaceuticals patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Vertex Pharmaceuticals patent portfolio.

How many patents does the Founder and CEO of Vertex Pharmaceuticals have?

The Founder Joshua Boger have 126 patents and the CEO Reshma Kewalramani have 10 patents.

How many patents does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals has a total of 12016 patents globally. These patents belong to 1429 unique patent families. Out of 12016 patents, 4501 patents are active.

How Many Patents did Vertex Pharmaceuticals File Every Year?

Vertex Pharmaceuticals Patents Filing Trend

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

Year of Patents Filing or GrantVertex Pharmaceuticals Applications FiledVertex Pharmaceuticals Patents Granted
2011669340
2012614413
2013522397
2014617353
2015304259
2016261256
2017228254
2018275298
2019292230
2020231231
2021166295
2022856

Which Vertex Pharmaceuticals Drug Patents are Expiring in the Next 10 Years?

The patent no. US8623905B2 which is expiring in May, 2027, describing adjusting a channel that responds to cAMP and ATP by increasing cAMP levels to activate CFTR.

Given below is the list of few drugs patented by Vertex Pharmaceuticals accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.

Drug NamePatent NumberPatent TitlePatent Expiration
Trikafta (Copackaged)US8623905B2Modulators Of ATP-Bind…May, 2027
Symdeko (Copackaged)US7776905B2Modulators Of ATP-Bind…Jun, 2027
OrkambiUS11564916B2Pharmaceutical Comp…Aug, 2029
KalydecoUS9670163B2Solid Forms Of N-[2,4-Bis…Dec, 2026
IncivekUS7820671B2Peptidomimetic Protease…Feb, 2025

How many Vertex Pharmaceuticals patents are Alive/Dead?

Worldwide Patents

Vertex Pharmaceuticals Patents Portfolio

How Many Patents did Vertex Pharmaceuticals File in Different Countries?

Vertex Pharmaceuticals Worldwide Patents

Countries in which Vertex Pharmaceuticals Filed Patents

CountryPatents
United States Of America1466
Europe867
Japan840
Australia682
India630
Hong Kong (S.A.R.)584
Canada522
China512
Germany385
Mexico359
Israel355
Korea (South)335
New Zealand315
Spain283
Singapore252
Russia239
Taiwan226
South Africa198
Austria192
Brazil163
Argentina160
Denmark150
Portugal140
Poland137
Norway127
Slovenia113
Chile86
Hungary76
Croatia73
Cyprus65
Serbia60
Lithuania57
Eurasia56
Ukraine52
Malaysia50
Albania44
Indonesia42
Uruguay36
Viet Nam35
Peru35
Africa30
Turkey24
Philippines24
Czech Republic24
Slovakia23
Georgia22
Montenegro17
Colombia17
Bulgaria14
Ecuador14
Former Yugoslav Republic of Macedonia9
Iceland9
Macao9
Estonia8
Luxembourg6
Panama6
Costa Rica6
Morocco6
San Marino5
Dominican Republic4
Romania4
Jordan4
Kenya3
Netherlands3
Ireland3
Finland3
Tunisia2
Republic of Moldova2
Brunei2
Yugoslavia/Serbia and Montenegro1
Saudi Arabia1
Kyrgyzstan1
Nicaragua1
Algeria1

Where are the Research Centers of Vertex Pharmaceuticals Patents Located?

Research Centers of Vertex Pharmaceuticals Patents

10 Best Vertex Pharmaceuticals Patents

WO2005095400A1 is the most popular patent in the Vertex Pharmaceuticals portfolio. It has received 506 citations so far from companies like Incyte Corporation, Almirall Sa and Biomea Fusion Llc.

Below is the list of 10 most cited patents of Vertex Pharmaceuticals:

Publication NumberCitation Count
WO2005095400A1506
US6344465B1411
US6498178B2405
WO2006127587A1361
WO2007056341A1355
WO2002022601A1351
WO2004111014A1319
WO2005075435A1314
WO2004072063A1314
US6686193B2269

Which Companies are using Vertex Pharmaceuticals Patents to Advance their Research?

If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.

The top citing companies in the Vertex Pharmaceuticals patent portfolio are Biomed Valley Discoveries Inc, Merck Sharp & Dohme Corp and Abbvie Inc.

List of the top forward citing Companies –

CompanyNumber of Patents
Biomed Valley Discoveries Inc9
Merck Sharp & Dohme Corp8
Abbvie Inc7
Deep Science Llc5
Novartis4
Gilead Pharmasset Llc4
Concert Pharmaceuticals3
Acea Biosciences Inc3
Arqule Inc3
Otsuka Pharmaceutical Co Ltd3

Count of 102 and 103 Type Rejections based on Vertex Pharmaceuticals Patents

Top Vertex Pharmaceuticals Patents used in Rejecting Most Patent Applications

Patent NumberCount of Rejected Applications
US7361492B216
US6686193B213
US7354939B29
US20100011610A16
US8431615B26
US7219545B26
US20100256184A15
US6969449B24
US7495014B23
US7615356B23
US7547794B23
US20070218138A13
US20070225297A13
US6638926B23
US7498166B23

What Percentage of Vertex Pharmaceuticals US Patent Applications were Granted?

Vertex Pharmaceuticals (Excluding its subsidiaries) has filed 1667 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 1067 have been granted leading to a grant rate of 76.3%.

Below are the key stats of Vertex Pharmaceuticals patent prosecution at the USPTO.

Which Law Firms Filed Most US Patents for Vertex Pharmaceuticals?

Law FirmTotal ApplicationsSuccess Rate
Vertex Pharmaceuticals Incorporated81173.52%
Jonathan P O Brien PhD Vpi24253.72%
Haley Guiliano Llp13288.19%
Dechert Llp5295.56%
Barnes & Thornburg Llp3983.87%
Knobbe Martens Olson & Bear Llp33100.00%
Life Technologies Corporation2180.95%
Troutman Pepper Hamilton Sanders Llp1877.78%
Lisa A Dixon17100.00%
Nandakumar Govindaswamy1533.33%

EXCLUSIVE INSIGHTS COMING SOON!

What are Vertex Pharmaceuticals key innovation segments?

What Technologies are Covered by Vertex Pharmaceuticals?

The chart below distributes patents filed by Vertex Pharmaceuticals in different countries on the basis of the technology protected in patents. It also represents the markets where Vertex Pharmaceuticals thinks it’s important to protect particular technology inventions.

R&D Focus: How has Vertex Pharmaceuticals search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Vertex Pharmaceuticals?

Related Articles

Arashi Vision Patents – Insights & Stats (Updated 2024)

Arashi Vision has a total of 1257 patents globally, out of which 751 have been granted. Of these 1257 patents, more than 87% patents are active. China is where Arashi Vision has filed the maximum number of patents, followed by United States of America and Europe (EPO). Parallelly, China seems

Read More »

Terecircuits Patents – Insights & Stats (Updated 2024)

Terecircuits has a total of 43 patents globally, out of which 22 have been granted. Of these 43 patents, more than 37% patents are active. United States of America is where Terecircuits has filed the maximum number of patents, followed by Europe (EPO) and Taiwan. Parallelly, United States of America

Read More »

Leave a Comment

Fill the form to get the details:

Our comprehensive report provides an in-depth look into the patent portfolio. The report includes a breakdown of the patent portfolio across various technologies, listing the patent along with brief summaries of each patent's technology.